Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | CASR | P41180 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | BMP1 | P13497 | 4/20 | 0.39 |
| ▸ | MMP2 | P08253 | 8/20 | 0.39 |
| ▸ | MMP3 | P08254 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4897016 | 0.85 | MMP3 (0.48) | CASRPOLBCTDSP1BMP1MMP2 | |
| SCHEMBL4907951 | 0.84 | MAPT (0.47) | — | |
| SCHEMBL4906479 | 0.82 | CTSS (0.45) | EPHX2CTSKMMP3MEN1KMT2A | |
| SCHEMBL8354345 | 0.80 | EPHX2 (0.50) | EPHX2CASRPOLBCTDSP1CTSK | |
| SCHEMBL4817847 | 0.79 | EPHX2 (0.49) | EPHX2CASRPOLBCTDSP1CTSK | |
| Hydrochloric Acid SCHEMBL4815550 | 0.79 | EPHX2 (0.49) | EPHX2CASRPOLBCTDSP1CTSK | |
| SCHEMBL8354664 | 0.78 | CTSK (0.48) | EPHX2CASRPOLBCTDSP1CTSK | |
| SCHEMBL4907652 | 0.74 | CTSK (0.59) | EPHX2CASRPOLBCTDSP1CTSK | |
| SCHEMBL6194925 | 0.70 | POLB (0.52) | EPHX2CASRPOLBCTDSP1MMP2 | |
| SCHEMBL29753182 | 0.70 | EPHX2 (0.80) | EPHX2CASRPOLBBMP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CATALANO JOHN G | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CTSK, CTSS, CTSE | EPHX2 2447/4885CASR 2818/4885POLB 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.